Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

Biotechnology

Healthcare
$9.38 +0.00%

+$0.00 today

Market cap
$622.71M
Beta
-0.53
P/E (TTM)
-8.8
EPS (TTM)
-$2.59
52W Low $8.48High $24.25

Volume 1.30M

Average 0.54M

BCAX Effect of Forex Changes

Change in reported cash caused by exchange-rate movements on foreign-currency balances.

Bicara Therapeutics Inc. Common StockNASDAQ: BCAX

Effect of Forex Changes · Q1 FY2026 · quarter ended Mar 2026

Effect of forex changes outflow grows to $0

Q1 FY2026 effect of forex changes was $0, compared with $0 a year earlier. Trailing-twelve-month effect of forex changes was $0.

Context

  • Effect of forex changes increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly effect of forex changes holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0-100.0% YoY
Effect of Forex Changes past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Effect of Forex Changes history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Effect of Forex Changes vs competitors

How BCAX compares with its peers on the latest reported figures

  • BCAX's LTM Mar 2026 effect of forex changes of $0 is the 2nd largest of the 6 companies compared; the peer median is $0.
  • Its year-over-year change of -100.0% is the lowest of 2, against a peer median of +157.3%.
BCAX Competitors Peer median
Effect of Forex Changes for BCAX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CBIOCrescent Biopharma, Inc.LTM Mar 2026$23.94M +157.3%—201.5%
BCAXBicara Therapeutics Inc. Common StockLTM Mar 2026$0 -100.0%——
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$0 ———
MGNXMacroGenics, Inc.LTM Mar 2026$0 ——0.0%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$0 ———
CNTXContext Therapeutics Inc.LTM Mar 2026$0 ———
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding BCAX) $0+157.3%—100.7%

Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(37.85M)(51.99M)(68M)(137.95M)
Depreciation & Amortization10K19K56K406K
Deferred Income Tax0000
Stock-Based Compensation810K1.9M7.4M15.01M
Change in Working Capital4.95M(9.62M)(14.13M)14.81M
Accounts Receivables0000
Inventory0000
Accounts Payables002.64M0
Other Working Capital4.95M(9.62M)(16.77M)14.81M
Other Non-Cash Items810K14.06M(77K)895K
Operating Cash Flow(32.08M)(45.63M)(74.75M)(106.83M)
Capital Expenditures(192K)(586K)(71K)(280K)
Acquisitions (Net)0000
Purchases of Investments000(318.17M)
Sales of Investments0000
Other Investing Activities0062K0
Investing Cash Flow(192K)(586K)(9K)(318.45M)
Debt Repayment0000
Common Stock Issued00332.43M32.26M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities160K149K1.6M0
Financing Cash Flow31.7M272.5M334.03M32.26M
Effect of Forex Changes0000
Net Change in Cash(573K)226.28M259.27M(393.03M)
Free Cash Flow(32.27M)(46.21M)(74.82M)(107.11M)

Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

Intrinsic Alpha fair value

Locked

Current Price

$9.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.